Sign In
Buy GLPG
$27.38
+0.0650 (+0.238%)
At Close: Jun 03, 2026
Selvita completes acquisition of Fidelta from Galapagos
04:01pm, Monday, 04'th Jan 2021
Mechelen, Belgium and Krakow, Poland – 04 January 2021, 22.01 TIME CET – Galapagos NV (Euronext & NASDAQ: GLPG) and Selvita S.A. (WSE: SLV) announced today that the strategic transaction in which
Galapagos: Market Values Pipeline Below $0
05:49am, Wednesday, 30'th Dec 2020
Due to the FDA's rejection of Filgotinib's 200 mg dosage for commercialisation in the US. Galapagos' earnings potential has been hampered severely. Yet, the current net cash position exceeds the compa
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
03:24pm, Saturday, 26'th Dec 2020
New York, New York--(Newsfile Corp. - December 26, 2020) - Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors ar
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
09:59pm, Wednesday, 16'th Dec 2020
New York, New York--(Newsfile Corp. - December 16, 2020) - Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors ar
Galapagos Stock Crumbles After Its Gilead Arthritis Deal Falls Apart
10:51am, Wednesday, 16'th Dec 2020
Gilead Sciences cut its losses on a rheumatoid arthritis treatment in partnership with Galapagos, sending GLPG stock tumbling on Wednesday. Gilead stock also fell less than 1%.
Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)
04:15pm, Tuesday, 15'th Dec 2020
FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amend their
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
06:50pm, Saturday, 12'th Dec 2020
NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV (“Galapagos” or the “Company”) (NASDAQ: GLPG). Such investors are
3 Stocks That Are Giving Their Investors Coal in Their Stockings
07:20am, Saturday, 12'th Dec 2020
Naughty or nice, shareholders aren't getting anything on their wish lists from these stocks this year.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
05:17pm, Thursday, 10'th Dec 2020
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are advised to contac
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q3 2020 Results - Earnings Call Transcript
09:21pm, Friday, 06'th Nov 2020
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q3 2020 Results - Earnings Call Transcript
Gilead Sciences Fails At Filgotinib - What's Next?
09:52am, Thursday, 20'th Aug 2020
Gilead Sciences recently announced the FDA response from Filgotinib, responses that put the future of the multi-billion drug program in doubt.
G1 Therapeutics' NDA Accepted, And Other News: The Alpha And Omega Of Biopharma
12:41am, Thursday, 20'th Aug 2020
G1 Therapeutics receives FDA acceptance of its Small Cell Lung Cancer NDA. Gilead suffers setback on filgotinib NDA front.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
12:01am, Thursday, 20'th Aug 2020
Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are advised to contact Robert S. Willoughby at newaction@poml
Why Galapagos Stock Is Crashing Today
04:18pm, Wednesday, 19'th Aug 2020
What happened Shares of Galapagos (NASDAQ: GLPG) were crashing 24.6% lower as of 11:14 a.m. EDT on Wednesday. The big drop came after the biotech's partner, Gilead Sciences (NASDAQ: GILD), announced t
Two Surprising FDA Rejections Raise Alarms for Biotech Investors
04:00pm, Wednesday, 19'th Aug 2020
(Bloomberg) -- The Food and Drug Administration’s rejection of a pair of medicines that Wall Street expected to sail by regulators raised concerns that other upcoming drug decisions could meet a sim
